Interleukin-6 receptor antagonist included in the new crown treatment plan

Xinhua News Agency, Geneva, July 6.
The World Health Organization updated its guidelines on the care of patients with COVID-19 on the 6th, including interleukin-6 receptor antagonists in the list of available drugs
.

This is the effective drug for the treatment of the new crown that has been reconfirmed since the WHO recommended the use of corticosteroids in September 2020
.

The WHO previously initiated a study of these drugs, which included data from more than 10,000 patients in 27 clinical trials
.

Studies have shown that compared with standard treatments, the use of interleukin-6 receptor antagonists in critically ill patients with new coronary disease can reduce the mortality rate by 13%, and the number of deaths per 1,000 critically ill patients can be reduced by 28, and mechanical ventilation for critically ill patients The odds of deficiencies have been reduced by 28%, and the number of patients requiring mechanical ventilation can be reduced by 23 per thousand
.

WHO Director-General Tedros Adhanom Ghebreyesus said in a statement issued on the same day that these drugs bring hope to critically ill patients and their families
.

The WHO calls on pharmaceutical companies to lower prices and supply drugs to low- and middle-income countries, especially those with a surge in new crown cases